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The mitochondria-active tetrapeptide SS-31 can control oxidative tissue damage 
in kidney diseases. To investigate other potential beneficial nephroprotective effects 
of SS-31, in vivo murine models of acute tubular injury and glomerular damage were 
developed. Reduction of acute kidney injury was demonstrated in mice treated with 
SS-31. The expression of mRNAs involved in acute inflammatory and oxidative stress 
responses in the diseased kidneys confirmed that SS-31 could regulate these pathways 
in our in vivo models. Furthermore, ex vivo histoenzymography of mouse kidneys showed 
that aminopeptidase A (APA), the enzyme involved in the processing of angiotensin 
(Ang) II to Ang III, was induced in the diseased kidneys, and its activity was inhibited by 
SS-31. As the renin–angiotensin system (RAS) is a main regulator of kidney functions, 
the modulation of Ang receptors (ATR) and APA by SS-31 was further investigated using 
mRNAs extracted from diseased kidneys. Following acute tubular and/or glomerular 
damage, the expression of the AT1R mRNA was upregulated, which could be selectively 
downregulated upon SS-31 administration to the animals. At the same time, SS-31 
was able to increase the expression of the AT2R, which may contribute to limit renal 
damage. Consequently, SS-31-based prodrugs were developed as substrates and/or 
inhibitors for APA and were screened using cells expressing high levels of APA, showing 
its selective regulation by α-Glu-SS-31. Thus, a link between SS-31 and the RAS opens 
new therapeutic implications for SS-31 in kidney diseases.
Keywords: oxidative stress, renin–angiotensin system, aminopeptidase A, experimental kidney disease, acute 
renal injury
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INTRODUCTION
Within the kidney, oxidative stress injury to glomerular, tubular, 
or endothelial cells is the initiating cause of many acute and 
chronic lesions, leading to progressive dysfunction and end-
stage renal disease (Lv et al., 2018; Daenen et al., 2019). An 
oxidative stress may be induced by either metabolic disorders 
and inflammation, such as hypertension and diabetes, or drug 
toxicity such as radiology contrast agents, antibiotics, and 
anticancer chemotherapeutics (Hulse and Rosner, 2019). The 
main organelle producing reactive oxygen species (ROS) is the 
mitochondria, but other metabolic pathways may also produce 
an oxidative stress and induce various stress responses in the 
kidney. ROS can either directly damage biological structures or 
indirectly activate cellular signaling pathways that are deleterious 
to the normal function of organs. Reducing ROS generation in 
response to tissue stress may prevent injury to the kidney (Koga 
et al., 2012). Thus, antioxidants, by scavenging oxidants or by 
inhibiting oxidative stress pathways, are interesting agents to 
protect tissues and organs. However, active oxygen species are 
also fundamental cellular signaling mediators and effectors, 
necessary for several important physiological processes.
Several antioxidants have been evaluated in experimental 
models of acute kidney injury and clinical trials, including 
superoxide dismutase (SOD) mimetics, glutathione, 
N-acetylcysteine, vitamin E, lipoic acid analogs, and, more recently, 
the cell-permeable mitochondria-active tetrapeptide SS-31 
(D-Arg-dimethylTyr-Lys-Phe-NH2, Elamipretide/Bendavia) 
(reviewed in Tabara et al., 2014). SS-31 selectively targets the 
mitochondrial inner membrane and prevents oxidative stress by 
enhancing oxidative phosphorylation coupling, thus improving 
ATP production. SS-31 was shown in several cellular and animal 
models to protect the kidney against ischemic injury by reducing 
death of tubular cells and by enhancing the proliferation of 
surviving tubular cells (Zhao et al., 2004; Thomas et al., 2007; 
Szeto et al., 2011; Kloner et al., 2012; Szeto, 2014; Eirin et al., 2014; 
Tabara et al., 2014). SS-31 also controls organ damage mediated 
by the NF-κB pathway (Mizuguchi et al., 2008; Huang et al., 
2013) decreasing the production of pro-inflammatory cytokines 
(Imig and Ryan, 2013) and the recruitment of macrophages and 
neutrophils (Szeto et al., 2011). However, cellular pathways other 
than direct anti-oxidative and inflammatory responses may be 
involved in the beneficial effects of SS-31.
Our main aims in the present report were to determine 
which beneficial effect SS-31 has on stress responses leading 
to glomerular and tubular injuries, and consequently to design 
targeted tissue-selective analogs of SS-31 as prodrugs. We 
therefore first evaluated the protective effect of SS-31 in two 
murine models of kidney diseases: acute tubulo-interstitial injury 
following aristolochic acid (AA) administration and adriamycin 
(ADR)-induced progressive glomerular damage. Using these 
experimental models, we determined the level of induction of 
oxidative stress-related molecules, inflammatory mediators, 
and cell proliferation pathways in the injured kidneys, in the 
absence or presence of SS-31. We also studied the modulation 
of the renin–angiotensin system (RAS), a major mediator of 
renal diseases when overactivated (Zhong et al., 2017). In the 
past years, we have investigated the therapeutic potential of 
specific drug-targeting strategies (Berger et al., 2000; Berger 
et al., 2003). More recently, we have designed functionalized 
inhibitors of the cell membrane-inserted enzyme γ-secretase 
(a component of the Notch signaling pathway) as substrates 
for the cell-surface peptidase γ-glutamyltranspeptidase (γ-GT) 
that is upregulated in acutely injured renal tubular cells. These 
prodrugs were shown to specifically enhance exposure of the 
kidneys to the therapeutic inhibitors (Juillerat-Jeanneret et al., 
2015; Wyss et al., 2018). Based on these previous results, we have 
designed and evaluated prodrugs of SS-31 as potential substrates 
and/or inhibitors of aminopeptidase A (APA), a peptidase also 
overexpressed in rodent and human injured kidneys (Song et al., 
1994; Troyanovskaya et al., 1996; Wolf et al., 2000).
MATERIALS AND METHODS
Synthesis Procedures
Mass spectra were recorded on an SSQ7000 (Finnigan-MAT) 
spectrometer for electron impact ionization. Liquid chromatography–
mass spectrometry (LC/MS) was recorded on Agilent 1290 LC 
with CTC PAL coupled to Agilent 6520 QTOF. High-pressure 
liquid chromatography (HPLC) was performed on column: 
symmetry C18, 5 µm, 250 × 4.6 mm, and 100 Å; buffer A: 0.1% 
trifluoroacetic acid (TFA) in water; buffer B: 0.1% TFA in 
CAN; gradient: (depending of peptide sequence) in 30 min at 1 
ml/min; temperature: 25°C; and detector: 210 nm.
Preparation of SS-31 and Analogs
All peptides were purchased from Polypeptide France and 
were prepared by manual solid phase peptide synthesis using 
the 9-fluorenylmethyloxycarbonyl (Fmoc) strategy. The 
C-terminal phenylalanyl residue was coupled to the resin 
(p-methylbenzhydrylamine polystyrene–1% divinylbenzene) 
via a Rink amide linker [p-(Fmoc-2,4-dimethoxybenzyl)-
phenoxyacetic acid]. The other amino acid residues were 
incorporated by a succession of Fmoc deprotection and amino 
acid coupling cycles. After solid-phase assembling of the peptide, 
the cleavage reaction from the resin and a concomitant side-chain 
deprotection in one step with TFA yielded directly the crude 
peptide with C-terminal amides. The crude preparation was 
precipitated and dried. Purification was performed by preparative 
reverse-phase HPLC in the TFA buffer. Each purified peptide 
obtained was tested by ion pair chromatography–HPLC against 
the specification before entering the final lot. The selected pools 
were mixed to form a homogeneous solution in water before 
freeze-drying and packaging.
SS-31 (D-Arg-DMT-Lys-Phe-NH2.3TFA) was synthesized by 
solid-phase peptide synthesis as described above using Fmoc-L-Phe, 
Fmoc-L-Lys(BOC)-OH, (S)-Fmoc-2,6-dimethyltyrosine, and Fmoc-
D-Arg(Pbf)-OH to give the final peptide. MS: 640.39 (M + H)+.
α-Glu-SS-31 (H-Glu-D-Arg-DMT-Lys-Phe-NH2.2TFA) was 
synthesized by solid-phase peptide synthesis as described above using 
Fmoc-L-Phe, Fmoc-L-Lys(BOC)-OH, (S)-Fmoc-2,6-dimethyltyrosine, 
Fmoc-D-Arg(Pbf)-OH, and Fmoc-L-Glu(OtBu)-OH.H2O to give 
the final peptide. MS: 769.44 (M + H)+.
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γ-Glu-SS-31 (H-γ-Glu-D-Arg-DMT-Lys-Phe-NH2.2TFA) was 
synthesized by solid-phase peptide synthesis as described above 
using Fmoc-L-Phe, Fmoc-L-Lys(BOC)-OH, (S)-Fmoc-2,6-
dimethyltyrosine, Fmoc-D-Arg(Pbf)-OH, and Fmoc-L-Glu(OH)-
OtBu to give the final peptide. MS: 769.66 (M + H)+.
Animal Models of Induced Kidney 
Diseases
All experiments were conducted in accordance with federal 
and local regulations, according to a protocol approved by the 
animal ethics committee of the Canton de Vaud, Switzerland 
(No. 2655.0). Kidney injury was induced by intraperitoneal 
(i.p.) injection of AA (Sigma-Aldrich, 1 × 5 mg/kg) or ADR 
(Adriblastin, Pfizer, 1 × 10 mg/kg) in 10-week-old BALB/c male 
mice (n = 5–7 mice/experimental group). SS-31 analogs were 
diluted in 0.9% NaCl and administered i.p. once a day, starting 1 
day before the disease-inducing drugs (day −1) at a dose of 3 mg/
kg and then daily until day 6. The animals were weighted at days 
0, 3, and 6, and sacrificed at day 7. The level of protein in urine was 
semi-quantitatively assessed using Albustix reagent strips (Bayer, 
Basel, Switzerland). At the end of the treatment period, the mice 
were sacrificed to remove both kidneys. The kidneys were spliced 
in four equal fragments containing the cortex and medulla. One 
fragment was immediately snap-frozen in liquid nitrogen for 
real-time quantitative polymerase chain reaction (qRT-PCR) 
and Western blot experiments, one fragment was included in 
OCT (Tissue-Tek, VWR International, Dietikon, Switzerland) 
and frozen for histoenzymography, one fragment was frozen at 
−80°C and used for pharmacokinetic (PK) measurements, and 
one fragment was fixed in 4% paraformaldehyde and included 
in paraffin for histology. Hematoxylin/eosin and Masson’s 
trichrome blue stainings of paraffin-embedded mouse kidney 
sections were performed using standard routine procedures to 
evaluate the level of kidney damage.
HPLC Procedures and PK of SS-31 
Analogs in Mouse Plasma, Liver, 
and Kidney
For PK evaluation, SS-31 was administered i.p. to male mice 
in suspension (gelatine/saline 7.5%/0.62% in water) using an 
administration volume of 4 ml/kg. Blood samples were collected 
in tubes containing EDTA as an anticoagulant, and plasma was 
separated by centrifugation and stored at −80°C. Liver and kidney 
samples (~100 mg aliquots) were homogenized in three volumes 
of water using Precellys tissue homogenization tubes (precellys.
com). Twenty-five microliters of each tissue homogenate was 
further diluted with 25 µl blank plasma to produce the final 
tissue homogenate for extraction. Prepared samples were stored 
at −20°C before analysis.
All samples were analyzed using protein precipitation 
followed by LC-MS/MS analysis. Briefly, 50 µl plasma or 
final tissue homogenate was mixed with 50 µl 0.5 M HClO4/
acetonitrile 9/1 (containing 200 ng/ml bosentan as an internal 
standard). Samples were stirred and 300 µl water was added, 
followed by centrifugation at 5600 rpm (4°C, 10 min). Ten 
microliters of supernatant was analyzed by LC/MS. Calibration 
standards in plasma were prepared the same way. The LC 
columns and conditions used were as follows: Phenomenex, 
Polar RP, 4 µm, and 50 × 2.1 mm at 0.4-ml/min flow rate with a 
3-min gradient from 95% solvent A to 95% solvent B (solvent A: 
water/acetonitrile/HCOOH, 90:10:0.1 with 10 mM NH4 formate; 
solvent B: water/ACN/HCOOH, 10:90:0.1 with 10 mM NH4 
formate). Mass spectrometric conditions were as follows: Thermo 
TSQ Vantage with positive heated electrospray ionization in MS/
MS mode. Mass transitions of the compounds were m/z 320.7 to 
119.9. Relative concentrations of the drug and metabolites were 
established by the percentage of peak area ratio compared to 
time zero spiked compounds. PK parameters for all studies were 
calculated using Phoenix WinNonlin Software.
Histoenzymography
Enzymatic activities were evaluated by histoenzymography on 
OCT-embedded frozen kidneys sections (7 µm), as previously 
described (Juillerat-Jeanneret et al., 1992; Juillerat-Jeanneret 
et al., 2000; Juillerat-Jeanneret et al., 2003). Briefly, slides were 
fixed for 5 min in cold (−20°C) acetone, air dried at room 
temperature, rehydrated for 5 min in 0.9% NaCl, and exposed 
to the α-Glu-4-methoxy-β-naphtylamide (APA; Bachem) or 
γ-Glu-4-methoxy-β-naphtylamide (γ-GT; Serva) substrates and 
Fast Blue B (Sigma-Aldrich) at 37°C for 15 to 60 min until a red 
coloration was visible. The slides were washed in distilled water, 
counterstained with hematoxylin (Mayer) for 1 min, rinsed under 
tap water and then with Scott solution for 1 min, and mounted 
in Aquamount (Immu-mount; Thermo Shandon, Pittsburgh, PA, 
USA) and analyzed with a Nikon Eclipse E800 microscope and 
digital DXM1200 camera using ACT-1 software.
Real-Time Quantitative PCR
Total RNA was extracted from frozen kidney fragments of 
either untreated mice or mice treated with the various drugs 
(n = 5–7 mice per experimental group) using the TRIzol 
reagent (Life Technologies, USA) as per the manufacturer’s 
instructions. Briefly, 10 mg kidney sample was homogenized 
using a polytron (VWR International). The nucleic acids were 
purified by chloroform/isopropanol extraction, quantified 
with the NanoDrop-ND2000 (Thermo Scientific, USA), and 
treated by DNase (Promega, USA). DNase-treated RNA samples 
(260:280-nm absorbance ratio of 1.9–2.0) were subjected to 
cDNA synthesis with the iScript™ cDNA Synthesis Reverse 
Transcription (RT) kit (Bio-Rad Laboratories, USA) as per the 
manufacturer’s instructions. For gene expression profiling, SYBR 
Green (SensiMixTM SYBR kit, Quantace)-based qPCRs were 
performed for quantification of a particular transcript using 
specific primers with Rotor-Gene 6000 instrument (Corbett 
Research, Australia). Intron spanning and exon-specific 
primers (sequences provided in Supplementary Table S1) were 
designed and synthesized (Microsynth, Switzerland). Standard 
curve analysis (>80% efficiency with single melting curve) 
was performed to validate the primers, and PCR amplicons 
were checked on ethidium bromide-containing agarose gels. 
To calculate the relative changes in mRNA expression, the 
ddC(T) method was used (Livak and Schmittgen, 2001). Gene 
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expression levels were normalized to Gapdh, and the control 
animal group was assigned 100%.
Cells and Culture Conditions
The preparation and characterization of rat brain-derived EC219 
endothelial cells were previously described (Juillerat-Jeanneret 
et al., 1992). These cells express high levels of APA and γ-GT 
activities and can be used to measure kinetics in living cells as 
APA and γ-GT-positive representative cell models. The cells 
were grown in Dulbecco’s modified Eagle medium (DMEM) 
containing 1 g/L glucose, 10% heat-inactivated fetal calf serum 
(FCS), and antibiotics on uncoated cell culture plastic plates and 
flasks. MDCK and LLCPK cells were obtained from the American 
Tissue Culture Collection (ATCC, Manassas, VA, USA) and 
were grown in DMEM containing 4.5 g/L glucose, 10% FCS, 
and antibiotics. mCCD, and mDCT cells were a kind gift from 
O. Bonny (UNIL, Lausanne, Switzerland) and were cultured in 
DMEM (Ham’s F12 1:1 vol/vol, 60 nM sodium selenate, 5 μg/ml 
transferrin, 50 nM dexamethasone, 1 nM triiodothyronine, 10 
ng/ml epidermal growth factor, 5 μg/ml insulin) and 2% FCS. The 
characteristics of the used cell lines are shown in Supplementary 
Table S2.
Determination of Enzyme Kinetics in 
EC219 Cells
Stock solutions of α-Glu-AMC (APA) and γ-Glu-AMC and Gly-
Gly (γ-GT) substrates, all from Bachem, were prepared at 10 mM 
in DMSO. EC219 cells were grown to confluence in 96-well plates 
(Corning, NY, USA), then the culture medium was removed, 
and the cell layers washed once with 100 µl PBS and 100 µl of 
substrates at decreasing concentrations (320–10 µM) of α-Glu-
AMC or γ-Glu-AMC and 20 mM Gly-Gly substrates diluted in 
PBS and increasing concentrations (0–20 µM) of SS-31 analogs 
were added. The increase in absorbance was measured at 37°C 
in a thermostated fluorescence multiwell-plate reader (CytoFluor 
Series 4000; PerSeptive Biosystems, MA, USA) at λex = 360 nm/
λem = 460 nm using the linear portion of the curves. The kinetics 
values were then graphically determined or according to Wu and 
colleagues (Wu et al., 2011).
Western Blots
EC219 cells were grown in RPMI medium containing 10% FCS 
and antibiotics until 95% confluence. Then 0.1 µM angiotensin 
(Ang) II (Bachem), 10 µM losartan (Sigma-Aldrich), and 100 µM 
SS-31, either alone or in combination, were added for 24 h. The 
cell layers were washed in PBS and the pellets suspended in the 
SDS-PAGE protein loading buffer. SDS-PAGE electrophoresis 
was performed in 10% gels, and the proteins were transferred 
to a PVDF membrane (Bio-Rad Laboratories). The membranes 
were probed sequentially with a rabbit monoclonal anti-AT1R 
antibody (clone ab124734, dilution 1/500; Abcam), followed by 
an anti-rabbit IgG-HRP antibody (dilution 1/1000; Cell Signaling 
Technology) and Radiance Plus (Azure Biosystems, Dublin, CA). 
The whole process was repeated on the same membrane with the 
anti-AT2R antibody (Abcam; ab92445, dilution 1/500) and the 
anti-β-actin antibody (clone 4967, dilution 1/2500; Cell Signaling 
Technology). Images of chemiluminescence were taken using 
FUSION-FX (Fisher Biotec). Membranes were analyzed using 
Photofiltre software and GelAnalyzer software (lazarsoftware).
Statistical Analysis
Results were averaged for all animals, and means ± SD were 
calculated. The level of statistical significance between experimental 
groups was assessed using a paired Student’s t-test or one-way 
analysis of variance along with Tukey’s post-test for multiple 
comparisons (GraphPad Prism version 6, California). p Values < 
0.05 were considered significant (*p < 0.05, **p < 0.01, ***p < 0.001).
RESULTS
In Vivo PK and Nephroprotective Effects of 
SS-31 in Experimental Acute Kidney Injury
Our first aim in this research was to explore whether SS-31 
had beneficial effects on stress responses in acutely injured 
kidneys other than by controlling the mitochondrial oxidative 
stress response as previously described (Szeto et al., 2011) and 
accordingly to design targeted and tissue-selective SS-31 analogs. 
Using a murine experimental model, we first determined the 
PK of SS-31 in mouse plasma, liver, and kidney following i.p. 
administration (Table 1). Following a 30-mg/kg injection, the 
maximal concentration of SS-31 was reached after 1 h and was 
comparable in the plasma, the liver, and the kidney, but the total 
concentration AUCinf was slightly higher in the kidney compared 
to the other organs, which is also reflected by a longer half-life 
(T1/2). SS-31 dosage corresponded to a mean kidney concentration 
(total kidney extract) of SS-31 (MW 639.79 g/mol) of ~140 nM.
The potential nephroprotective effects of SS-31 were evaluated 
in the in vivo murine models of acute renal tubulo-interstitial or 
glomerular injury, selectively induced by AA or ADR, respectively. 
The histological evaluation of the organs retrieved from the 
experimental mice after 1 week confirmed the development of 
acute kidney damage in the two models, more acutely severe after 
AA exposure (Figure 1A). The administration of AA induced 
extensive tubulo-interstitial lesions (mainly affecting proximal 
tubules), resulting in acute kidney insufficiency (mean creatinine 
258 ± 92 µmol/L vs. 44 ± 5 µmol/L, in the AA and control groups, 
respectively), rapid weight loss, and death of the animal depending 
on its severity. Figure 1A indeed shows distorted tubular 
architecture with loss of brush borders in the proximal tubules, 
focal necrosis, and tubules filled with hyaline casts and cells debris. 
In comparison, ADR administration results mainly in glomerular 
podocyte injury and inflammation, which is evidenced clinically 
TABLE 1 | In vivo pharmacokinetics of SS-31 after i.p. administration (30 mg/kg) 
in male mice; plasma, liver and kidney exposures. (n = 6 mice).
Plasma Liver Kidney
Cmax [ng/ml] 19992 12695 17236
Tmax [h] 1.0 1.0 1.0
AUC4h [h*ng/ml] 21120 20709 27801
AUCinf [h*ng/ml] 21138 22101 31280
T1/2 [h] 0.3 0.9 1.1
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FIGURE 1 | Experimental mouse models of kidney diseases. Kidney injury was induced either by i.p. injection of aristolochic acid (AA, 1x5mg/kg) or adriamycin 
(ADR, 1x10mg/kg) in 10 weeks old BALB/c male mice (n = 7 animals per experimental group). (A) Hematoxylin/eosin (H&E) or Masson’s trichrome blue (MTB) 
staining of kidney sections of healthy wild-type control mice and mice treated with ADR or AA, without (above and middle panels) or with SS-31 (lower panels). 
Representative renal cortical sections per experimental groups are shown (200x magnification). (B) Renal injury was induced by ADR or AA. SS-31 (3 mg/kg) was 
administered i.p. once a day, starting one day before the disease-inducing drugs (day −1) and then daily until day 6 (dotted lines) (n = 5 mice per experimental 
group). The animals were monitored clinically daily, weighted and the level of albuminuria was semi-quantitatively assessed at day 0, day 3 and day 6, and averaged 
for all animals. Results are presented as means ± sd for all mice in each experimental group, with comparisons between SS-31-treated versus non-SS-31-treated 
diseased animals (***p < 0.001).
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FIGURE 2 | Expression of the oxidative stress pathway-responsive genes in the kidneys of mice exposed to aristolochic acid or adriamycin, without or with SS-31. 
Acute renal injury was induced by i.p. injection of aristolochic acid (AA) or adriamycin (ADR) in 10 weeks old BALB/c male mice (n = 5 mice per experimental group), 
without or with the administration of SS-31 (AA + SS31 or ADR + SS31). At the end of the experiment (day 7), the animals were sacrificed and mRNAs were 
extracted from the snap-frozen kidneys. Healthy wild-type BALB/c male mice were used as controls (Cont). The levels of expression of the mRNAs for hypoxia 
inducible factor1-α (HIF-1α), heme oxygenase-1 (HO-1), superoxide dismutase-1 (SOD1), SOD2 and cyclooxygenase-2 (COX-2) were quantified by qRT-PCR. 
Results were averaged for all animals in each experimental group and are presented as % of changes in the mRNA levels in the treated animals versus control 
animals ± sem. *: AA or ADR compared to Cont; #: AA + SS-31 or +: ADR + SS-31 compared to AA or ADR alone, respectively. (*p < 0.05; **p < 0.01; ***p < 0.001; 
applies to all symbols).
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FIGURE 3 | Expression of acute pro-inflammatory pathway-responsive genes in the kidneys of mice exposed to aristolochic acid or adriamycin, without or with SS-31. After 
7 days of administration of either aristolochic acid (AA) or adriamycin (ADR), alone or together with SS-31 (+SS31), the animals (n = 5 mice per experimental group) were 
sacrificed and their kidneys retrieved for the determination by qRT-PCR of the mRNA levels of genes of components of acute inflammatory pathways. Healthy wild-type 
BALB/c male mice were used as controls (Cont). The levels of expression of the mRNAs for interleukin (IL)-β, IL-6, nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB)1, NF-κB2 and cyclin-dependent kinases (CDK2 and CDKN1A) were quantified by qRT-PCR. Results were averaged for all animals in each experimental group 
and are presented as % of changes in the mRNA levels in the treated animals versus control animals ± sem.*: AA or ADR compared to Cont; #: AA + SS-31 or +: ADR + 
SS-31 compared to AA or ADR alone, respectively. (*p < 0.05; **p < 0.01; ***p < 0.001; applies to all symbols).
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by rapid-onset proteinuria but more progressive and late kidney 
dysfunction following focal glomerular sclerosis (mean creatinine 
33 ± 5 µmol/L at the time of sacrifice, in the ADR group). 
Accordingly, diseased (AA and ADR-treated) and SS-31-treated 
mice were monitored throughout the experiments for weight 
and proteinuria (Figure 1B). SS-31 administration statistically 
improved albuminuria in the ADR model of glomerular damage, 
while in the AA model, SS-31-treated mice were more protected 
against acute kidney failure and its consequences as reflected 
by statistically better kidney function (mean creatinine 162 ± 
21 µmol/L) and a trend toward less weight loss at the end of the 
experiment. Kidney histology of mice exposed to either AA or 
ADR was also better preserved under SS-31 treatment.
Effects of SS-31 on Induced Stress 
Responses and Inflammation During 
Acute Renal Injury
One week after the onset of disease, control wild-type mice, AA- or 
ADR-administered mice, and SS-31-treated mice were sacrificed, 
and the kidneys were retrieved for the determination by qRT-
PCR of markers of oxidative stress (Figure 2), inflammation, 
and cell proliferation (Figure 3). The regulatory effect of SS-31 
on enzymes associated with oxidative stress, including hypoxia-
inducible factor 1α (HIF-1α), cyclooxygenase-2 (COX-2), and 
heme oxygenase-1 (HO-1), was model dependent (Figure 2). In 
both experimental models, mRNA levels of HIF-1α, HO-1, and 
COX-2 were significantly increased, and SS-31 could restore these 
levels only for HIF-1α and HO-1 (as compared to control mice), 
in AA- and ADR-administered mice, respectively. Surprisingly, 
treatment with SS-31 further increased the expression of COX-2 
in acutely damaged kidneys. In our experimental setting, the 
expression of superoxide dismutase-1 (SOD1) at the mRNA level 
was not significantly affected during acute renal injury, while 
SOD2 expression was downregulated and partially restored after 
SS-31 treatment in the AA model. Attempts to directly measure 
ROS production in kidney sections were not successful using our 
experimental models.
We next evaluated the expression of genes involved in acute 
inflammatory pathways and the effect of SS-31 in kidneys 
of mice exposed to AA and ADR (Figure 3). Except for the 
expression of the transcription factor nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB)1, SS-31 
treatment did not reduce the expression of inflammatory genes 
FIGURE 4 | Modulation of genes of the renin–angiotensin system in the kidneys of mice exposed to aristolochic acid or adriamycin, without or with SS-31. After 7 
days of treatment with either aristolochic acid (AA) or adriamycin (ADR), alone or together with SS-31 (+SS31), the animals (n = 5 mice per experimental group) were 
sacrificed and their kidneys retrieved for the determination by qRT-PCR of the mRNA levels of genes of the components of the renin–angiotensin system (RAS). 
Healthy wild-type BALB/c male mice were used as controls (Cont). The levels of expression of the mRNAs for aminopeptidase A (APA), the AT1 and AT2 angiotensin 
receptors were quantified by qRT-PCR. Results were averaged for all animals in each experimental group and are presented as % of changes in the mRNA levels in 
the treated animals versus control animals ± sem.*: AA or ADR compared to Cont; #: AA + SS-31 or +: ADR + SS-31 compared to AA or ADR alone, respectively.  
(*p < 0.05; **p < 0.01; ***p < 0.001; applies to all symbols).
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in the AA model, possibly because of the severity of induced 
kidney lesions as seen in the histological slides (Figure 1). In the 
ADR model, SS-31 treatment could regulate the expression of 
the pro-inflammatory cytokine interleukin (IL)-6 and NF-κB2 
at the mRNA level. Finally, we analyzed the expression of cell 
proliferation markers in our experimental setting and the effect 
of SS-31 treatment. Similar to early inflammatory pathway-
associated genes, SS-31 treatment could not modulate the 
upregulation of cyclin-dependent kinase 2 (CDK2), an enzyme 
involved in the G1-S transition phase of the cell cycle, induced 
during severe acute kidney injury after AA administration. SS-31 
could, however, regulate the expression of this gene following 
ADR administration, which resulted in less acutely severe 
inflammation (IL-1β, IL-6) and renal damage on histology.
Effects of SS-31 on Components of  
the RAS
Beyond the hemodynamic effects of the RAS in the kidney, local 
activation of this pathway has been associated with renal damage, 
and as such, RAS blockers are often administered to patients 
with chronic kidney disease (Kobori et al., 2007; Urushihara and 
Kagami, 2017). Overactivation of the angiotensin type 1 receptor 
(AT1R) by the octapeptide Ang II promotes the development 
and progression of several kidney diseases via signaling cascades 
involving inflammation and fibrosis, whereas the activation 
of AT2R may counterbalance AT1R activation, thus being 
beneficial. Conversion of Ang II to Ang III is critical for AT2R-
mediated effects in the kidney since Ang III is the major agonist 
of AT2R (Padia et al., 2008). Ang III is released from Ang II by 
the action of APA removing the N-terminal Asp of Ang II. To 
evaluate the effect of SS-31 on the RAS, we therefore determined 
the expression of AT1R, AT2R, and APA in the kidneys of mice 
exposed to either AA or ADR, without or with SS-31. Following 
both tubulo-interstitial or glomerular damage induced by AA 
or ADR administration to the mice, significant downregulation 
of the expression of APA mRNA was observed by qRT-PCR 
(Figure  4) in renal tissues, which was nearly restored by 
concomitant SS-31 treatment. Accordingly, AT1R mRNA levels, 
which were upregulated during acute kidney injury mediated 
by AA or ADR, decreased upon SS-31 treatment. Interestingly, 
at least in the AA group, SS-31 also upregulated the expression 
of AT2R mRNA. Overall, in addition to acute oxidative stress, 
inflammatory and proliferative pathways induced locally during 
renal tissue injury, SS-31 could modulate the RAS, notably by 
regulating the expression of APA and consequently of AT2R.
FIGURE 5 | Expression of AT1R and AT2R proteins by EC219 cells exposed to Ang II, an AT1R antagonist (losartan) and SS-31. The expression of AT1R and AT2R by 
EC219 cells exposed for 24 h to either Ang II, the AT1R antagonist losartan or SS-31, or their combination, were analyzed by western blotting: (one representative 
blot, (A), then quantified (3 experiments, (B) by comparison with the expression of β-actin as a control. (**p < 0.01; ***p < 0.001).
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We next analyzed whether SS-31 could directly regulate 
the expression of AT1R and AT2R at the protein level. For this 
purpose, we used an in vitro cellular model that expresses 
these receptors (as previously characterized and published, 
Juillerat-Jeanneret et al., 1992), exposed to Ang II, losartan 
(a specific AT1R antagonist used in the clinic), SS-31, or 
their combination (Figure 5). SS-31 was able to increase the 
expression of AT2R and in combination with losartan to control 
FIGURE 6 | Chemical structures of SS-31 and the evaluated functionalized analogs. The prodrugs are composed of the active compound (SS-31) and the targeting 
α-Glu or γ-Glu-moiety as substrates for the enzymes aminopeptidase A (APA) and γ-Glu-transpeptidase (γ-GT), respectively.
FIGURE 7 | Selective inhibition of the enzymatic activities of aminopeptidase A and γ-glutamyltranspeptidase by SS-31, α-Glu-SS-31 or γ-Glu-SS-31 determined by 
histoenzymography in the kidneys of mice exposed to adriamycin. Sequential sections (7 µm) of frozen OCT-embedded kidneys of adriamycin (ADR)-treated mice 
were exposed at 37°C to β-methoxynaphthylamide (β-NA) specific substrates of aminopeptidase A (α-Glu-βNA, upper panels) or γ-glutamyltranspeptidase (γ-Glu-
βNA, lower panels) and Fast Blue B, in the absence (none) or the presence of SS-31, α-Glu-SS-31 or γ-Glu-SS-31. The sections were then counterstained with 
light hematoxylin reagent. The enzymatic activity is visualized as a red precipitate. For the negative control, we used Fast Blue B in the absence of β-NA substrate. 
Representative renal cortical sections per experimental groups are shown (200x magnification).
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AT1R upregulation. Therefore, these protein data support the in 
vivo mRNA expression levels showing the regulation by SS-31 
of the RAS in acutely injured mouse renal tissues, including the 
expression of AT2R. This information suggests that SS-31, alone 
or in combination with RAS blockers, may be of clinical interest 
for developing nephroprotective therapies.
Design and ex Vivo and in Vitro Evaluation 
of Functionalized Analogs of SS-31
As shown in Table 1, similar amounts of SS-31 were found in the 
plasma, liver, and kidneys of wild-type mice after i.p. injection, 
which could result in generalized off-target effects during 
therapeutic administration. Thus, enhancing the biodistribution 
of this peptide selectively to the kidney, in particular to the 
diseased renal tissue, may be a valuable option to enhance 
therapeutic efficacy while decreasing exposure of non-diseased 
organs. We had previously observed highly increased enzymatic 
activities of the peptidases APA and γ-GT in selective 
compartments of diseased kidneys in rodent experimental 
TABLE 2 | Stability of SS-31 and α-Glu-SS-31 in mouse plasma. 
Time [h] Stability [% of T0] Release of SS-31
SS-31 α-Glu-SS-31 from α-Glu-SS-31 
[%]
0 100 100 7.5
0.5 89.3 68.5 9
1 85.3 68.3 9
3 50.1 66.9 10
5 43 65.8 9
SS-31 or α-Glu-SS-31 (at 1 μM concentration) was added to heparinized plasma obtained 
from healthy wild-type mice and incubated at 37°C. Aliquots were removed at 0, 0.5, 1, 3 
and 5 h and analyzed. Stability is expressed as [%] of initial concentration at T0.-
FIGURE 8 | Selective inhibition of the enzymatic activity of aminopeptidase A by SS-31 and its prodrug α-Glu-SS-31 in living EC219 cells. (A) Intact living EC219 
cells were exposed to increasing concentrations of either amastatin (left panel) or acivicin (right panel), two well-characterized enzymatic activity inhibitors of APA 
or γ-GT, respectively. The activities of the enzymes aminopeptidase A (APA) or γ-glutamyltranspeptidase (γ-GT) were determined using 40 µM of the substrates 
(S), α-Glu-AMC or γ-Glu-AMC, respectively. (B) Intact living EC219 cells were exposed to increasing concentrations [10-320 µM] of the APA α-Glu-AMC substrate, 
in the presence of increasing concentrations of SS-31 or α-Glu-SS-31, and the increase of free AMC fluorescence was recorded. Data were analyzed graphically. 
(DMSO 0.2% was present in all samples).
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models as well as in human samples (Juillerat-Jeanneret et al., 
2015). We therefore designed prodrugs of SS-31 as substrates for 
these enzymes by adding either α-Glu (as a substrate for APA) or 
γ-Glu (as a substrate for γ-GT) at the N-terminus of SS-31. The 
chemical structures of the compounds are shown in Figure 6.
First, we evaluated the effects of SS-31, α-Glu-SS-31, and 
γ-Glu-SS-31 on the activities of APA and γ-GT using an ex vivo 
approach by histoenzymography on histological slides of frozen 
kidney samples of mice exposed to ADR for 7 days (Figure 7). 
For these proof-of-concept assays, we limited our experiments to 
the ADR model in which kidney structures are better preserved 
because of less severe acute lesions. Using this model, we confirmed 
our previous data showing the increased enzymatic activity of the 
enzymes APA and γ-GT in the kidneys of ADR-exposed mice 
when compared to wild-type mice, mainly in the glomerulus and 
proximal tubular cells (results not shown; Juillerat-Jeanneret et al., 
2015). The enzymatic activity of APA was selectively inhibited by 
SS-31 and α-Glu-SS-31, its cognate substrate, but not γ-Glu-SS-31 
(not shown), whereas the activity of γ-GT was modified neither by 
SS-31 or by its cognate substrate γ-Glu-SS-31, suggesting a more 
interesting potential of APA for developing substrate prodrugs.
In order to analyze the effects of SS-31 and its selective analogs, 
previously characterized renal epithelial cell lines and non-renal cells 
were screened to determine their levels of APA and γ-GT enzymatic 
activities (Supplementary Table S2). In comparison to the available 
renal epithelial cell lines, the EC219 rat endothelial cells expressed 
very high levels of both enzymatic activities (Juillerat-Jeanneret 
et al., 1992). We therefore used intact living EC219 cells to compare 
the inhibitory effects of SS-31 and α-Glu-SS-31 on APA enzymatic 
activity (Figure 8). To validate the inhibition methodology, we 
determined as controls the inhibition of APA by amastatin and 
of γ-GT by acivicin, two validated synthetic inhibitors of these 
enzymes. DMSO used as solvent for the different drugs had only 
very limited effect of the activities of the enzymes (data not shown). 
We observed the selective inhibition of APA activity in EC219 cells 
by SS-31 and α-Glu-SS-31, its cognate substrate, but not γ-Glu-SS-31 
(data not shown), while neither SS-31 nor α-Glu-SS-31 was able to 
inhibit the activity of γ-GT in intact EC219 cells (data not shown). 
The IC50 values for APA inhibition were determined to be 8.5 ± 3.8 
µM for SS-31 and 13.7 ± 6.7 µM for α-Glu-SS-31. Thus, both SS-31 
and α-Glu-SS-31 displayed comparable inhibitory potential of APA 
activity, with IC50 being only very slightly lower for free SS-31.
Finally, we determined if α-Glu functionalization of SS-31 
would improve the plasma stability of the compound. SS-31 or 
α-Glu-SS-31 (at 1 µM concentration) was added to heparinized 
mouse plasma, and the aliquots were incubated at 37°C for various 
time points before analysis (Table 2). After a rapid decrease of 
α-Glu-SS-31 concentration, associated with the appearance of free 
SS-31, in mouse plasma, the concentration of both compounds 
remained stable for up to 5 h, whereas SS-31 concentration 
decreased regularly during the same period of time.
DISCUSSION
Excessive ROS production in response to acute inflammatory 
disorders or toxic injuries causes oxidative damage to lipids, 
nucleic acids, and proteins, leading to tissue dysfunction, whereas 
physiological production of ROS is critical for cell signaling and 
homeostasis. Therefore, ROS levels are tightly regulated by complex 
cellular anti-oxidative systems. ROS are mainly the products of 
mitochondrial oxidative phosphorylation. Mitochondrial changes 
are a feature of kidney diseases, suggesting that reducing ROS 
generation may be of therapeutic interest. Several therapeutics, 
including DHL-HisZn, a lipoic acid derivative; probucol, an 
anti-hyperlipidemic drug with ROS scavenging properties; or 
metformin, an anti-diabetic, were shown to have anti-oxidative 
properties and to enhance renal recovery after ischemia–reperfusion 
injury (Morales et al., 2010; Koga et al., 2012; Zhou et al., 2013). 
Antioxidant tetrapeptides based on the YRFK (Tyr-Arg/D-Arg-
Phe-Lys) peptide sequences, conjugated to a triphenylphosphonium 
moiety to improve pharmaco-chemical stability, have been designed 
(Akhmadishina et al., 2018). Other mitochondrial-penetrating 
peptide sequences based on cyclohexylAla and D-Arg have been 
evaluated (Hidaka et al., 2017). An interesting molecule in this 
context is the mitochondria-targeting antioxidant tetrapeptide SS-31 
(D-Arg-2,6-dimethyltyrosine-Lys-Phe-NH2, Bendavia). SS-31 
belongs to a family of aromatic cationic peptides that selectively 
target the mitochondrial inner membrane and can scavenge ROS, an 
effect mediated by the dimethyl-Tyr group of the peptide (Zhao et al., 
2004; Dai et al., 2011) reducing mitochondrial production of ROS. 
SS-31 has been shown to improve the course of diverse experimental 
models of kidney diseases associated with mitochondrial oxidative 
stress (Szeto et al., 2011; Zhao et al., 2013; Tabara et al., 2014; Szeto 
et al., 2016; Sweetwyne et al., 2017; Danielle et al., 2018). SS-31 was 
also shown to improve pulmonary hypertension in murine models 
of the disease (Lu et al., 2015), atherosclerotic plaques in mice in 
part by increasing SOD activity (Zhang et al., 2017), or oxidative 
stress in cells from patients with Friedreich ataxia, a progressive 
neurodegenerative disease (Zhao et al., 2017).
To investigate potential beneficial nephroprotective effects of 
SS-31 other than direct anti-oxidant properties, we developed two 
in vivo murine models of acute tubular and glomerular damage 
mediated by toxic compounds. AAs are a family of 10-nitro-1-
phenantropic acids derived from tyrosine. AA is a natural herbal 
compound that is toxic to the renal tubulo-interstitial compartment, 
leading to a rapidly progressive nephropathy, renal failure, and, in 
some instances, cancer of the urinary tract. AA-induced tubular 
toxicity involves mitochondrial permeability and injury, leading 
to defective activation of anti-oxidative enzymes, combined with 
progressive tubular atrophy, impaired regeneration, and apoptosis/
autophagy of proximal tubular epithelial cells (Romanov et al., 
2011; Zeng et al., 2014). The anticancer drug doxorubicin (ADR) 
and its metabolites accumulate in the inner mitochondrial 
membrane, producing excessive ROS and causing oxidative 
damage. ADR administration results in a more progressive kidney 
disease characterized by massive proteinuria due to podocyte 
injury, glomerulosclerosis, tubulo-interstitial inflammation, and 
fibrosis (Okuda et al., 1986; Mukhopadhyay et al., 2009; Lee and 
Harris, 2011; Gao et al., 2014). Cardiolipin, a lipid of interest for 
SS-31 functions, was shown to interact with doxorubicin (Aryal 
and Rao, 2016). In the present report, we showed that SS-31 could 
alleviate the severity of nephropathy in mice exposed to AA or 
ADR. We also showed that SS-31 reduced the upregulation at the 
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mRNA levels of the stress response-associated NF-κB signaling 
pathway. SS-31 also modulated the expression of genes involved 
in hypoxia and oxidative stress (mainly HIF-1α in the AA and 
HO-1 in the ADR model), in our experimental setting. Thus, using 
different models of acute nephropathy, our results extend and 
confirm previous experimental data showing the protective role of 
SS-31 against acute oxidative stress injuries and inflammation in 
the kidney and other organs (Mizuguchi et al., 2008; Szeto et al., 
2011; Huang et al., 2013).
Interestingly and unexpectedly, we observed that, beyond the 
regulation of acute oxidative stress and associated inflammatory 
responses, SS-31 could directly modulate the expression of 
members of the RAS, in particular APA and AT2R. The RAS is a 
main regulator of kidney functions, being modulated and acting 
independently in the blood and the kidney (Sparks et al., 2014). 
All the RAS components have been found in the kidney, with 
AT1R and AT2R being differentially expressed in renal tissues. 
Ang II via AT1R mediates most of the classical functions of the 
RAS. Non-hemodynamic actions of AT1R include enhanced 
generation of ROS, oxidative stress, and inflammatory responses. In 
cardiomyocytes and podocytes, Ang II/AT1R activation can induce 
apoptosis mediated by mitochondrial fission (Qi et al., 2018). 
AT2R counteracts AT1R effects, with AT2R being abundant during 
fetal development but also detectable in adult tissues, including 
the kidney (Mukoyama et al., 1993). In the adult kidney, AT2R is 
expressed by glomerular, vascular and tubular cells (particularly 
highly expressed in proximal tubules). AT2R stimulation can 
inhibit inflammation involving NF-κB, reduce organ damage, and 
promote tissue repair and regeneration. The effects of the AT2R 
agonists C21 or NP-6A4 (Toedebush et al., 2018) suggest that AT2R 
activation may limit renal damage, in part mediated by improved 
function of mitochondria. Thus, AT1R and AT2R display opposing 
functions and selectivity (Carey and Padia, 2013). In the intact 
kidney, the Ang II/AT1R axis is predominant in response to initial 
injury, stimulating oxidases to produce ROS, inducing oxidative 
and inflammatory stresses. The Ang II/Ang III/AT2R axis becomes 
apparent following pathological conditions, when ongoing local 
injury increases AT2R expression. APA is a membrane-bound 
zinc-dependent aminopeptidase broadly expressed in the kidney 
(located at the surface of glomerular vascular and mesangial cells 
as well as of podocytes and proximal tubules). Conversion of 
Ang II to Ang III (desAsp1-Ang II) by APA is critical for AT2R-
mediated effects in the kidney since Ang III is the major agonist 
of AT2R (Wolf et al., 1997; Padia et al., 2008; Kemp et al., 2012). 
SS-31 displays an N-term-Arg, as does Ang III, which stabilizes 
the binding of Ang III to AT2R. This may represent a physiological 
response to kidney stresses, including oxidative stress. We have 
previously shown that transforming growth factor β can regulate 
APA expression (Juillerat-Jeanneret et al., 2000). Similarly, others 
have shown a role for several cytokines and growth factors 
(Suganuma et al., 2004), linking APA regulation to inflammatory 
pathways. As pharmacological interventions for the treatment of 
many nephropathies involve agents that block the RAS (Thomas 
and Groop, 2011; Lambers Heerspink and de Zeeuw, 2013), our 
observations of a link between SS-31, the RAS, and inflammatory/
oxidative stress reactions have implications for potential therapeutic 
effects of SS-31 besides its direct anti-oxidative properties.
As ROS also play important roles in normal physiology, 
chronic inhibition of ROS may result in off-target responses 
and side effects. Previous attempts have been done to increase 
mitochondria targeting of therapeutic drugs, mostly using 
conjugation of agents to various compounds (Wolf et al., 1997, 
Wolf et al., 2000), including nanoparticles (Hidaka et al., 2017; 
Akhmadishina et al., 2018; Battogtokh et al., 2018; Mattarei 
et  al., 2018; Shi et al., 2018). We have previously shown that 
high enzymatic activities of the peptidases APA and γ-GT 
in diseased human and rat kidneys may represent targets to 
develop prodrug therapeutics (Juillerat-Jeanneret et al., 1992; 
Juillerat-Jeanneret et  al., 2015). In our murine models, APA 
activity was expressed in the glomerular tuft and proximal 
tubular cells, while γ-GT activity was confined to proximal 
tubular epithelial cells. Using similar experimental models. we 
have previously developed prodrugs of γ-secretase inhibitors 
(GSI) as substrates for peptidases to control pathogenic Notch 
pathway activation. In this previous research, we demonstrated 
that targeting γ-GT activity using a γ-Glu-linker-GSI was the 
preferred choice as compared to targeting APA activity (Wyss 
et al., 2018). For the present project, we directly bound α-Glu or 
γ-Glu to SS-31 using a peptide bond as functionalized prodrugs 
of SS-31, designed as substrates of these two peptidases. 
Whereas we previously showed that to achieve the targeting of 
prodrug inhibitors of the membrane-inserted γ-secretase was 
more efficient using substrates for γ-GT, we show here that for 
targeting SS-31 and mitochondrial pathways, the use of prodrug 
substrates for APA is to be preferred. In our experimental 
setting, SS-31 acted as an inhibitor of APA enzymatic activity, 
resulting in a slight upregulation of APA mRNA levels, likely as 
a feedback mechanism. Several inhibitors for this enzyme have 
been developed as potentially therapeutic (Mentzel et al., 1996; 
Mentzel et al., 1997; David-Basei et al., 2001; Gerlofs-Nijland 
et al., 2001; Chen et al., 2014). Thus, in addition to SS-31, such 
inhibitors associated with AT2R modulators may be of value in 
the context of kidney diseases.
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